Angel Biotechnology Holdings signed a development and GMP manufacturing deal with CellCure. Angel will manufacture and supply GMP materials for use in a T-cell based immuno-therapy as part of a Phase II trial to evaluate the treatment in patients with metastatic malignant melanoma.
"Having worked only with laboratory-grown T cells in the past, the development of a final and fully GMP compliant bio-pharmaceutical preparation is crucial to our future success,” points out Anders Trojel, CEO of CellCure.
The GMP production scale-up project, to be conducted at Angel's facilities, will last for 18 months.